Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company that discovers, develops, and commercializes next-generation therapeutics for unmet medical needs in central nervous system, respiratory, inflammatory, and cardiometabolic diseases. Its lead product candidate is brilaroxazine (RP5063), being developed for neuropsychiatric indications such as schizophrenia, bipolar disorder, major depressive disorder, ADHD, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. The company also conducts clinical development for respiratory indications including pulmonary arterial hypertension and idiopathic pulmonary fibrosis, and preclinical development for psoriasis, as well as RP1208 for depression and obesity. Founded in 2018, it is headquartered in Cupertino, California.